Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034619192> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3034619192 abstract "Hyperglucagonemia plays an important role in pathogenesis of T2DM. The effect of glucagon on the plasma lipidome has not been studied in humans. We examined the effect of prolonged glucagon infusion on plasma lipid metabolites in healthy subjects. 8 NGT subjects (5M/3F, age=35±5, BMI=24±1, A1c=5.3±0.3%) received 12-hour (6PM to 6AM) glucagon infusion (6ng/kg/min). On a different day the subjects returned for a repeat study with infusion (6PM to 6AM) of normal saline. Top-ranking plasma lipidomes were measured by shotgun lipidomics including Phosphatidylethanolamine (PE), Lysophosphatidylethanolamine (LPE), Phosphatidylcholine (PC), Lysophosphatidylcholine (LPC), Ceramide (CER), Sphingomyelin (SM), Acylcarnitine (AC), Phosphatidylglycerol (PG), Phosphatidylinositol (PI), Phosphatidylserine (PS), Triacylglycerol (TAG), Fatty Acyl Chains in TAG (FA). Plasma glucagon increased from 57±3 to 219±21 pg/ml. Plasma insulin increased significantly following glucagon compared to saline (20±7 vs. 8±3 mU/L, p<0.05) and remained elevated. Plasma LPE, PC, LPC, CER, SM, FFA, AC increased, plasma PE, PS declined, and PG, PI, FA did not change following 12-hour glucagon infusion. The greatest increase occurred with Lysophosphatidylcholine (LPC, 18:2) which rose ∼2.5 fold (126±11 vs. 51±7 nmol/ml, p<0.005) following glucagon infusion. LPCs and LPEs are generated after activation of phospholipase A2, along with the release of fatty acids, and have been reported to induce inflammation and the effector of fatty acid induced insulin resistance. On the other hand, reduced PE is observed in animal models of obesity, supporting its role as a substrate of phospholipase A2 activation. Increased ceramide levels also have been shown to incite inflammation. In conclusion, prolonged glucagon infusion modulates novel lipid metabolites involved in inflammation and represents a fundamental mechanism by which glucagon activates inflammation pathways, contributing to insulin resistance. Disclosure X. Chen: None. X. Han: None. J. Trejo: None. E. Case: None. R.A. DeFronzo: None. D. Tripathy: None. Funding Foundation for Advancement of Veteran’s Health and Research" @default.
- W3034619192 created "2020-06-19" @default.
- W3034619192 creator A5006281067 @default.
- W3034619192 creator A5008171524 @default.
- W3034619192 creator A5011359818 @default.
- W3034619192 creator A5024057589 @default.
- W3034619192 creator A5059543571 @default.
- W3034619192 creator A5073917506 @default.
- W3034619192 date "2020-06-01" @default.
- W3034619192 modified "2023-09-24" @default.
- W3034619192 title "1707-P: Differential Effect of Prolonged Glucagon Infusion on Plasma Lipidome in Humans" @default.
- W3034619192 doi "https://doi.org/10.2337/db20-1707-p" @default.
- W3034619192 hasPublicationYear "2020" @default.
- W3034619192 type Work @default.
- W3034619192 sameAs 3034619192 @default.
- W3034619192 citedByCount "0" @default.
- W3034619192 crossrefType "journal-article" @default.
- W3034619192 hasAuthorship W3034619192A5006281067 @default.
- W3034619192 hasAuthorship W3034619192A5008171524 @default.
- W3034619192 hasAuthorship W3034619192A5011359818 @default.
- W3034619192 hasAuthorship W3034619192A5024057589 @default.
- W3034619192 hasAuthorship W3034619192A5059543571 @default.
- W3034619192 hasAuthorship W3034619192A5073917506 @default.
- W3034619192 hasConcept C126322002 @default.
- W3034619192 hasConcept C134018914 @default.
- W3034619192 hasConcept C185592680 @default.
- W3034619192 hasConcept C2776330855 @default.
- W3034619192 hasConcept C2778563252 @default.
- W3034619192 hasConcept C2778596009 @default.
- W3034619192 hasConcept C2778918659 @default.
- W3034619192 hasConcept C2779306644 @default.
- W3034619192 hasConcept C2780241833 @default.
- W3034619192 hasConcept C2908748658 @default.
- W3034619192 hasConcept C41625074 @default.
- W3034619192 hasConcept C4733338 @default.
- W3034619192 hasConcept C55493867 @default.
- W3034619192 hasConcept C71924100 @default.
- W3034619192 hasConceptScore W3034619192C126322002 @default.
- W3034619192 hasConceptScore W3034619192C134018914 @default.
- W3034619192 hasConceptScore W3034619192C185592680 @default.
- W3034619192 hasConceptScore W3034619192C2776330855 @default.
- W3034619192 hasConceptScore W3034619192C2778563252 @default.
- W3034619192 hasConceptScore W3034619192C2778596009 @default.
- W3034619192 hasConceptScore W3034619192C2778918659 @default.
- W3034619192 hasConceptScore W3034619192C2779306644 @default.
- W3034619192 hasConceptScore W3034619192C2780241833 @default.
- W3034619192 hasConceptScore W3034619192C2908748658 @default.
- W3034619192 hasConceptScore W3034619192C41625074 @default.
- W3034619192 hasConceptScore W3034619192C4733338 @default.
- W3034619192 hasConceptScore W3034619192C55493867 @default.
- W3034619192 hasConceptScore W3034619192C71924100 @default.
- W3034619192 hasIssue "Supplement_1" @default.
- W3034619192 hasLocation W30346191921 @default.
- W3034619192 hasOpenAccess W3034619192 @default.
- W3034619192 hasPrimaryLocation W30346191921 @default.
- W3034619192 hasRelatedWork W1855195526 @default.
- W3034619192 hasRelatedWork W1978037308 @default.
- W3034619192 hasRelatedWork W1979975085 @default.
- W3034619192 hasRelatedWork W2002695797 @default.
- W3034619192 hasRelatedWork W2050763953 @default.
- W3034619192 hasRelatedWork W2091083050 @default.
- W3034619192 hasRelatedWork W2099375768 @default.
- W3034619192 hasRelatedWork W2400917451 @default.
- W3034619192 hasRelatedWork W2970161534 @default.
- W3034619192 hasRelatedWork W2337002345 @default.
- W3034619192 hasVolume "69" @default.
- W3034619192 isParatext "false" @default.
- W3034619192 isRetracted "false" @default.
- W3034619192 magId "3034619192" @default.
- W3034619192 workType "article" @default.